The 26th International AIDS Conference (AIDS 2026)

Rio de Janeiro, Brazil 26 July 2026 - 31 July 2026

Dolutegravir knocks down HIV faster than bictegravir in French study

06 Oct 2026 by

Final analysis of the BicDol study, presented at AIDS 2026, suggests that a first-line triple antiretroviral regimen containing dolutegravir suppresses HIV more rapidly than one containing bictegravir, particularly among patients with the highest viral loads.

06 Oct 2026

Delayed ART initiation, socioeconomic factors predict HIV care disengagement

01 Oct 2026 by

Delayed initiation of antiretroviral therapy (ART) and some socioeconomic factors contribute to disengagement from HIV care, suggests a study in the Philippines.

01 Oct 2026

Switch from complex to single-tablet regimen does not compromise HIV suppression

01 Oct 2026 by

Treatment with the single-tablet regimen (STR) doravirine/islatravir (DOR/ISL; 100/0.25 mg) results in sustained virologic suppression in almost all virologically suppressed adults with HIV-1 receiving complex antiretroviral therapy (ART) regimens, a study has shown.

01 Oct 2026

Two-drug noninferior to three-drug ART as initial HIV treatment

24 Sep 2026 by

In individuals with untreated HIV-1 infection, the two-drug dolutegravir/lamivudine (DTG/3TC) antiretroviral therapy (ART) regimen has similar efficacy as the three-drug bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen, according to the phase IIIb VOGUE study.

24 Sep 2026

Injectable HIV Tx trumps daily pill in virally suppressed adolescents

04 Sep 2026 by

The week-96 LATA trial results demonstrate the superiority of long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) to tenofovir/lamivudine/dolutegravir (TLD) for maintaining virologic suppression in adolescents with HIV in sub-Saharan Africa.

04 Sep 2026

Lenacapavir continues to serve its PURPOSE in OLE study

03 Sep 2026 by

Twice-yearly subcutaneous lenacapavir continues to show high efficacy and is well tolerated among cisgender men and gender-diverse individuals in the open-label extension (OLE) of the PURPOSE 2 trial.

03 Sep 2026

Doravirine-based ART matches dolutegravir-based regimen in efficacy with less weight gain

01 Sep 2026 by

Among treatment-naïve adults with HIV who are initiating antiretroviral therapy (ART), a regimen containing doravirine, lamivudine, and tenofovir disoproxil fumarate (DOR/3TC/TDF) is as good as the dolutegravir, emtricitabine, and tenofovir alafenamide (DTG/FTC/TAF) regimen in terms of viral suppression but is associated with less weight gain, according to the open-label, head-to-head OPTI-DOR study conducted in South Africa.

01 Sep 2026